Pleiotropic heritability quantifies the shared genetic variance of common diseases

Yujie Zhao[1,2], Benjamin Strober[2], Kangcheng Hou[2], Gaspard Kerner[2], John Danesh[3,4,5,6,7,8], Steven Gazal[9,10,11], Wei Cheng[1,12,13], Michael Inouye[3,4,5,7,14,15], Alkes L. Price*[2,16,17], Xilin Jiang*[2,3,4,16,18]

Correspondence: Y.Z. (yjzhao22@m.fudan.edu.cn), A.L.P. (aprice@hsph.harvard.edu), X.J. (xj262@medschl.cam.ac.uk)

*: co-senior authors.

[1] Institute of Science and Technology for Brain-Inspired Intelligence, Fudan University, Shanghai, China.
[2] Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA
[3] British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge UK
[4] Victor Phillip Dahdaleh Heart and Lung Research Institute, University of Cambridge, Cambridge UK
[5] British Heart Foundation Centre of Research Excellence, University of Cambridge, Cambridge, UK
[6] National Institute for Health and Care Research Blood and Transplant Research Unit in Donor Health and Behaviour, University of Cambridge, Cambridge, UK
[7] Health Data Research UK Cambridge, Wellcome Genome Campus and University of Cambridge, Cambridge, UK
[8] Department of Human Genetics, Wellcome Sanger Institute, Hinxton, UK
[9] Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
[10] Center for Genetic Epidemiology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
[11] Department of Quantitative and Computational Biology, University of Southern California, Los Angeles, CA, USA
[12] State Key Laboratory of Brain Function and Disorders (Fudan University), Ministry of Education; Shanghai, China.
[13] Fudan ISTBI—ZJNU Algorithm Centre for Brain-inspired Intelligence, Zhejiang Normal University, Zhejiang, China.
[14] Cambridge Baker Systems Genomics Initiative, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
[15] Cambridge Baker Systems Genomics Initiative, Baker Heart and Diabetes Institute, 75 Commercial Rd, Melbourne 3004, Victoria, Australia
[16] Broad Institute of MIT and Harvard, Cambridge, MA, USA
[17] Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA
[18] Cambridge Centre for AI in Medicine, University of Cambridge, Cambridge, UK

Abstract

Common diseases are highly pleiotropic, but the overall contribution of pleiotropy to a target
disease's architecture is unknown, as most studies focus on genetic correlations with each
auxiliary disease in turn. Here we propose a new method, pleiotropic heritability with bias
correction (PHBC), to estimate pleiotropic heritability (h^2_{pleio}), defined as the liability-scale
genetic variance of a target disease that is shared with a specific set of auxiliary diseases. We
estimate h^2_{pleio} from GWAS summary statistics by estimating the proportion of variance
explained from an estimated genetic correlation matrix and employing a Monte-Carlo bias
correction procedure to account for sampling noise in genetic correlation estimates. Simulations
showed that PHBC produces approximately unbiased estimates of pleiotropic heritability. The
average ratio of pleiotropic heritability vs. total SNP-heritability (h^2_{pleio}/h^2) across 15 diseases
from the UK Biobank (spanning 7 disease categories) was 27% (s.e. 2%). Pleiotropic heritability
was broadly distributed across disease categories, with h^2_{pleio}/h^2 decreasing only slightly when
removing all auxiliary diseases in the target disease category (avg = 24% (s.e. 2%)) and only
moderately when further removing one other (most informative) category whose removal had the
greatest impact (avg = 18% (s.e. 1%)). Average h^2_{pleio}/h^2 increased to 33% (s.e. 2%) when
adding 17 auxiliary quantitative traits in UK Biobank, and 49% (s.e. 4%) when further adding 30
auxiliary diseases from large GWAS meta-analyses—with several diseases dominated by
pleiotropic heritability, including depression (74%, s.e. 7%) and type 2 diabetes (59%, s.e. 4%).
On average, h^2_{pleio}/h^2 was 1.51x (s.e. 0.14) larger than the proportion of liability-scale total
phenotypic variance explained by the same set of auxiliary diseases, implying higher pleiotropy
for genetic effects than the effects of non-genetic exposures. In conclusion, we have uncovered
pervasive sharing of genetic aetiologies, with roughly half of common disease heritability being
pleiotropic with diseases from a broad range of disease categories, which strongly motivates the
importance of multi-disease approaches to risk prediction and therapeutic development.

Introduction

Common diseases and complex traits are highly pleiotropic and extensive efforts have been made to understand the shared components of disease risk[1–6]. Previous studies have quantified and characterized the shared genetic variance between pairs of diseases[7–14], identified latent genetic components that are shared across many diseases[15–23], and leveraged the sharing of genetic variant associations across diseases to increase association power[17,19,24–29]. However, to our knowledge, we lack a method to estimate the genetic variance of a given target disease that is shared with other diseases and traits.

To address this gap, we introduce pleiotropic heritability (h^2_{pleio}), which quantifies the genetic variance of a target disease that is shared with a specific set of auxiliary diseases and traits. We develop a new method, pleiotropic heritability with bias correction (PHBC), to estimate h^2_{pleio} from GWAS summary statistics. PHBC employs a Monte-Carlo bias correction procedure to correct bias arising from sampling noise in genetic correlation estimates due to finite GWAS sample size. We validate PHBC using extensive simulations then estimate h^2_{pleio} for 15 diseases in UK Biobank and, subsequently, for 30 diseases with GWAS summary statistics available from extensive meta-analyses. Finally, we extend PHBC to estimate the liability-scale total phenotypic variance of a target disease that is shared with a set of auxiliary diseases.

Results

Definition of pleiotropic heritability

We define pleiotropic heritability as the liability-scale genetic variance (from SNPs) of a target disease that is shared with a specific set of auxiliary diseases. We can view the genetic value of the target disease as the sum of a disease-specific genetic value that is not shared with the auxiliary diseases and a pleiotropic genetic value that is shared with auxiliary diseases (**Figure 1A**), with the variance of latter denoted the pleiotropic heritability (h^2_{pleio}). We use the ratio of pleiotropic heritability to total SNP-heritability (h^2_{pleio}/h^2) to quantify the proportion of genetic variance (from SNPs) that is pleiotropic. We note that the definition of pleiotropic heritability is dependent on both the target disease and the selected set of auxiliary diseases, and reflects specific phenotype definitions in specific cohorts.

In detail, h^2_{pleio} is the liability-scale variance explained by the weighted linear combination of auxiliary disease genetic liabilities that explains the maximum proportion of target disease heritability (in the entire population with infinite sample size):

$$h^2_{pleio}/h^2 = \max_{\alpha_j} \ r^2\left[\sum_{j=1}^{n} \alpha_j G_j , G_T\right] \tag{1}$$

where α_j is the weight of the jth auxiliary disease (D_j), r is a correlation across individuals, G_j is the genetic liability of D_j, and G_T is the genetic liability of the target disease; h^2_{pleio} is the corresponding r^2 with the total liability L_T instead of the genetic liability G_T.

Alternatively, we can define $h^2{}_{pleio}/h^2$ using the proportion of variance of causal SNP effect
sizes on the target disease explained by the weighted linear combination of causal SNP effect
sizes on the auxiliary diseases that explains the maximum proportion of variance:

$$h^2{}_{pleio}/h^2 = \max_{\alpha_j} r^2 \left[\sum_{j=1}^n \alpha_j \beta_j , \beta_T\right]$$ (2)

where α_j is the weight for the jth auxiliary disease (D_j), r is a correlation across SNPs, β_j is the
vector of standardized causal SNP effect sizes on D_j (the number of s.d. increase in phenotype
per 1 s.d. increase in genotype), and β_T is the vector of standardized causal SNP effect sizes on
the target disease. We note that under the assumption of no correlation between causal effect
sizes of SNPs in LD with each other, the two definitions are equivalent (**Methods**).

We note that when an auxiliary disease D_j has zero genetic correlation with the target disease, its
contribution to pleiotropic heritability of the target disease is zero. We emphasize that pleiotropic
heritability is different from the heritability contributed by pleiotropic variants; if an auxiliary
disease shares all causal variants with the target disease but with a genetic correlation of zero, its
contribution to pleiotropic heritability of the target disease is zero, but 100% of the target disease
heritability is contributed by pleiotropic variants. In this study, we restrict both pleiotropic
heritability and total heritability to the heritability contributed by common SNPs (see below).

Overview of estimation of pleiotropic heritability

We estimate $h^2{}_{pleio}$ from estimates of total SNP-heritability and genetic correlations between the
target and auxiliary diseases, and employ a Monte-Carlo bias correction procedure to obtain
unbiased estimates. We emphasize the need for a bias correction procedure: for example, if the
target disease has true genetic correlation of 0 with each auxiliary disease (implying true
pleiotropic heritability of 0), genetic correlation *estimates* will be nonzero due to sampling noise,
implying a pleiotropic heritability *estimate* greater than 0 in the absence of a bias correction
procedure. Monte-Carlo sampling is a widely used method that relies on random sampling to
capture properties of a noise distribution[30]. In our application, Monte-Carlo sampling captures
the noise distribution of the noisily estimated genetic correlations; when the sampled genetic
correlations are used to estimate $h^2{}_{pleio}/h^2$, the resulting distribution captures the bias in
$h^2{}_{pleio}/h^2$ arising from noisily estimated genetic correlations. Specifically, Monte-Carlo
sampling is used to estimate the expected ratio between the true value (unbiased) vs. initial
estimate (biased) of $h^2{}_{pleio}/h^2$, so that the initial estimate can be scaled by this ratio to obtain an
unbiased estimate. In this study, we apply cross-trait LD Score regression (LDSC)[8] to summary
association statistics and reference LD to estimate genetic correlations; we note that the cross-
trait LDSC estimand is the genetic correlation of causal effect sizes of common SNPs
(**Methods**). We obtain standard errors via genomic block-jackknife, as in cross-trait LDSC[8]. We
have publicly released open-source software implementing our method (**Code Availability**).

In detail, it can be shown that Eq. 2 is equivalent to (see **Methods**):

$$h^2{}_{pleio}/h^2 = r_g[\boldsymbol{D},T]^T r_g[\boldsymbol{D},\boldsymbol{D}]^{-1} r_g[\boldsymbol{D},T]$$ (3)

where h^2 is the SNP-heritability of the target disease, $r_g[\boldsymbol{D}, T]$ is the $n \times 1$ vector of genetic
correlations between the target and auxiliary diseases, and $r_g[\boldsymbol{D}, \boldsymbol{D}]$ is the $n \times n$ genetic correlation
matrix among the set of auxiliary diseases, where n is the number of auxiliary diseases
(**Methods**). We initially estimate h^2_{pleio}/h^2 by estimating the corresponding quantities in Eq. 3.
However, the errors in estimates of $r_g[\boldsymbol{D}, \boldsymbol{D}]$ and $r_g[\boldsymbol{D}, T]$ in finite GWAS sample size introduce
an upward bias in estimates of h^2_{pleio}/h^2, if $r_g[\boldsymbol{D}, \boldsymbol{D}]^{-1}$ is positive definite (which is likely to be
the case) (**Methods**).

To obtain an unbiased estimate, we first generate Monte-Carlo samples of estimation errors in
$r_g[\boldsymbol{D}, \boldsymbol{D}]$ and $r_g[\boldsymbol{D}, T]$ from the sampling covariance matrix computed from genomic block-
jackknife[17] (we use the same genomic block-jackknife for the target disease T and all auxiliary
diseases $\boldsymbol{D}$; see **Code Availability**); these samples capture the joint distribution of estimation
errors across elements in $r_g[\boldsymbol{D}, \boldsymbol{D}]$ and $r_g[\boldsymbol{D}, T]$. Then, we add the estimation errors to the point
estimates of $r_g[\boldsymbol{D}, \boldsymbol{D}]$ and $r_g[\boldsymbol{D}, T]$ to create Monte-Carlo samples of h^2_{pleio}/h^2, which are larger
than the initial estimate. We then use binary search to estimate a scaling coefficient ξ_c
multiplying $r_g[\boldsymbol{D}, T]$ so that the average h^2_{pleio}/h^2 across Monte-Carlo samples matches the
initial estimate of h^2_{pleio}/h^2 (see **Methods**). Finally, we multiply the initial estimate of
h^2_{pleio}/h^2 (and its standard error) by ξ_c^2 to obtain an unbiased estimate of h^2_{pleio}/h^2.

In the presence of collinearity among auxiliary diseases and uncertainty in genetic correlation
estimates, the estimate from Eq. 3 can be numerically unstable, which we define as
s.e.$(r_g[\boldsymbol{D}, T]^T r_g[\boldsymbol{D}, \boldsymbol{D}]^{-1} r_g[\boldsymbol{D}, T]) > 0.5$ and/or $\xi_c < 0.5$ (see **Methods**). Whenever this occurs,
we prune auxiliary traits as follows: for each pair of auxiliary traits with $r_g^2 > 0.5$, we remove
the trait with lower r_g z-score with target trait; we repeat this procedure for r_g^2 thresholds of 0.5,
0.4, 0.3, 0.2, and 0.1 until the estimate is numerically stable.

We extend our method to estimate the liability-scale total phenotypic variance of a target disease
that is shared with a specific set of auxiliary diseases (V^2_{pleio}) by estimating the liability-scale
phenotypic correlation between pairs of diseases using individual-level data[31] (**Figure 1B**). (We
note that the term pleiotropy generally refers to genetic effects, but we use the term pleiotropic
phenotypic variance for consistency.) Further details are provided in the **Methods** section.

An overview of empirical data analyzed is as follows. We first analyzed 15 highly heritable
target diseases (prevalence > 1%, heritability z-score > 6, and liability-scale heritability ranging
from 0.061 to 0.21) from the UK Biobank[32] (average N = 157K, spanning 7 PheCode disease
categories[33]) (**Table 1**); the sample size reflects a restriction to unrelated individuals of British
ancestry with diagnostic records from both primary care data and hospital inpatient data, which
we imposed to mitigate the impact of missing diagnoses. In our UK Biobank analyses, we used
the same 15 diseases as auxiliary diseases; we also performed analyses incorporating 17
quantitative traits[34,35] from the UK Biobank as auxiliary traits (including blood biochemistry
measurements, e.g. total cholesterol, blood pressure and HbA1c, and demographic traits, e.g.
height, BMI and years of education; details in **Supplementary Table 2** and **Methods**). We
subsequently incorporated 30 diseases with large meta-analyses available (average N = 483K) as
target and/or auxiliary diseases. In all analyses, we restricted to auxiliary diseases with modest
genetic correlation to the target disease ($r_g^2 < 0.5$). We have publicly released all summary

association statistics analyzed in this study, along with estimates of pleiotropic heritability and
related quantities (**Data Availability**). We note that while we elected to focus on target diseases,
definition and estimation of pleiotropic heritability is also applicable to target quantitative traits.
We recommend that users restrict to target and auxiliary traits that have heritability z-score > 6,
and auxiliary traits that have $r_g^2 < 0.5$ with the target trait (**Methods**).

Simulations

We performed simulations to evaluate the unbiasedness of pleiotropic heritability estimates. We
specified genetic architectures for 16 diseases using liability-scale heritabilities of 0.13 (median
of 15 UK Biobank diseases; **Table 1**) and prevalences of 0.1 (median of 15 UK Biobank
diseases; **Table 1**). True genetic correlations were set to 0.5 within disease categories and 0.1
between disease categories for the first 15 diseases (based on the 7 disease categories from **Table
1**) and 0.0 for the last disease (with each other disease), implying 5 different values of true
h^2_{pleio}/h^2 for each target disease (ranging from 0.00 to 0.38). The proportion of causal SNPs
was set to 5%. Additional simulation settings were also evaluated. We simulated phenotypes
from real UK Biobank genotypes using 1.1M HapMap3[36] SNPs across 157,206 unrelated
individuals. We applied PLINK2[37] to compute summary association statistics and applied cross-
trait LD score regression[8] to summary association statistics for the 1.1M SNPs (MAF > 0.01) and
reference LD from 1000 Genomes European individuals (9.3M SNPs) to estimate genetic
correlations. We then estimated h^2_{pleio} for each disease using the other 15 diseases as auxiliary
diseases. Further details of the simulation framework are provided in the **Methods** section.

Results are reported in **Figure 2** and **Supplementary Table 4**. Before Monte-Carlo bias
correction, h^2_{pleio}/h^2 estimates suffered upward biases (between 0.024 (s.e. 0.0012) and 0.028
(s.e. 0.0034); average bias of 0.026 (s.e. 0.0011)), highlighting the need for a bias correction
procedure. After Monte-Carlo bias correction, h^2_{pleio}/h^2 estimates were approximately unbiased
across the 16 simulated diseases with varying pleiotropic architectures. Most biases were small
(between -0.007 (s.e. 0.003) and 0.0078 (s.e. 0.0006); average bias of -0.0020 (s.e. 0.0011)). We
compared the estimated standard errors to empirical standard deviations, and determined that
estimated standard errors were conservative, with the ratio of the average estimated squared
jackknife standard error to the average empirical squared deviation equal to 1.63
(**Supplementary Figure 1** and **Supplementary Table 4**).

We performed six secondary analyses. First, we performed simulations with the proportion of
causal SNPs set to 1% (instead of 5%), and determined the results were similar to **Figure 2**
(**Supplementary Figures 2-3** and **Supplementary Table 11**). Second, we simulated pleiotropic
architectures with r_g within disease categories equal to 0.4, 0.3, or 0.2 (instead of 0.5) (and r_g
between disease categories still equal to 0.1), and observed approximately unbiased results
(**Supplementary Figures 4-5** and **Supplementary Tables 5-7**). Third, we performed
simulations with liability-scale heritabilities equal to 0.25 or 0.06 (instead of 0.13). We observed
approximately unbiased results with liability-scale heritability equal to 0.25 (**Supplementary
Figures 6-7** and **Supplementary Tables 8**). With liability-scale heritability equal to 0.06, we
observed modest downward bias for values of h^2_{pleio}/h^2 above 25% and modest upward bias
for values below 5%, with average bias of -0.017 (s.e. 0.0023) (**Supplementary Figures 8-9** and
Supplementary Tables 9). Fourth, we performed simulations with the prevalence set to 0.05

(instead of 0.1), and determined the results were similar to **Figure 2** (**Supplementary Figures**
10-11 and **Supplementary Table 10**). Fifth, we estimated h^2_{pleio}/h^2 without pruning highly
correlated auxiliary diseases, and we observed that h^2_{pleio}/h^2 estimates were approximately
unbiased (**Supplementary Figures 12-13** and **Supplementary Table 12**). Across these five
experiments, we determined that uncorrected estimates of h^2_{pleio}/h^2 suffered upward bias
(ranging from 1.1% (s.e. 0.12%) to 9.9% (s.e. 0.80%)), emphasizing the need for a bias
correction procedure. Finally, we performed simulations to evaluate the genomic block-jackknife
standard errors on the reduction in h^2_{pleio}/h^2 in analyses with one auxiliary disease category
removed, and determined that standard errors were conservative (**Supplementary Figure 14** and
Supplementary Table 13).
232

Application to 15 diseases from the UK Biobank

We estimated h^2_{pleio}/h^2 for 15 highly heritable target diseases from the UK Biobank
(heritability z-score > 6; average N=157K, liability-scale heritability ranging from 0.061 to 0.21,
spanning 7 PheCode disease categories[33]) (**Table 1**). Genetic correlations across these 15
diseases are reported in **Figure 3A** and **Supplementary Table 14**, and corresponding liability-
scale phenotypic correlations are reported in **Figure 3B** and **Supplementary Table 15**. We
observed moderate genetic correlations within disease categories and between disease categories,
and smaller phenotypic correlations.

Estimates of h^2_{pleio}/h^2 for three representative diseases (type 2 diabetes (T2D), depression
(MDD), and hypertension (HTN)), and the average across 15 diseases, are reported in **Figure 4**,
Supplementary Figure 15 and **Supplementary Table 17**. We determined that 27% of SNP-
heritability is pleiotropic on average (jackknife s.e.(avg) = 2%, s.d. = 19% across diseases); the
Monte-Carlo bias correction procedure had a substantial impact on estimates of h^2_{pleio}/h^2 (pre-
correction average = 38%, jackknife s.e.(avg) = 4%, **Supplementary Figure 16**,
Supplementary Table 17), consistent with simulations (**Figure 2**) and underscoring the
importance of correcting upward bias. Several diseases had fairly high h^2_{pleio}/h^2 estimates,
including 44% (s.e. 7%) for MDD and 45% (s.e. 5%) for T2D.

We performed three analyses in which we modified the set of auxiliary diseases (**Figure 4**,
Supplementary Figure 15 and **Supplementary Table 17**). First, we included 17 quantitative
traits from the UK Biobank (**Supplementary Table 2**) as additional auxiliary traits, causing
estimates of h^2_{pleio}/h^2 to increase (avg = 33%, jackknife s.e.(avg) = 2%, s.d. = 21%). Second,
we restricted to auxiliary diseases excluding the target disease category, causing estimates of
h^2_{pleio}/h^2 to decrease only slightly (avg = 24% (s.e. 2%); 41% (s.e. 6%) for MDD (removing
mental) and 36% (s.e. 5%) for T2D (removing endocrine)). Third, we further removed one other
disease category whose removal had the greatest impact, causing estimates of h^2_{pleio}/h^2 to
decrease only moderately (avg = 18% (s.e. 1%); 36% (s.e. 6%) for MDD (removing mental and
digestive) and 26% (s.e.5%) for T2D (removing endocrine and circulatory system)). These
results imply that pleiotropic heritability is broadly distributed across disease categories.

Estimates of h^2_{pleio}/h^2 with respect to auxiliary diseases in each individual disease category are
reported in **Figure 5**, **Supplementary Figure 17** and **Supplementary Table 19**. We determined

that auxiliary diseases from a single disease category can often explain the majority of
pleiotropic heritability. For example, MDD had 41% (s.e. 7%) and 31% (s.e. 2%) of SNP-
heritability shared with digestive and respiratory disease categories, respectively (vs. 44% for all
disease categories), consistent with the high pleiotropic overlap between brain-gut and brain-lung
axes in previous studies[38,39]); T2D had 33% (s.e. 4%) and 25% (s.e. 4%) of SNP-heritability
shared with circulatory and digestive disease categories, respectively (vs. 45% for all disease
categories), consistent with the importance of T2D-related processes in the etiology of
cardiometabolic diseases in previous studies[22]); and the 15 target diseases on average had 17%
(s.e. 3%) and 16% (s.e. 4%) of SNP-heritability shared with endocrine and mental disorder
categories, respectively (vs. 27% for all disease categories).

However, removing a single disease category from the set of auxiliary diseases generally reduced
h^2_{pleio}/h^2 much less than the h^2_{pleio}/h^2 shared with that disease category (**Figure 5**,
Supplementary Figure 17 and **Supplementary Table 19**). For example, MDD h^2_{pleio}/h^2 was
reduced by only 5% (s.e. 7%) and 0.1% (s.e. 1.5%) when removing digestive and respiratory
categories, respectively; T2D h^2_{pleio}/h^2 was reduced by only 7% (s.e. 4%) and 2% (s.e. 3%)
when removing circulatory and digestive disease categories, respectively; and average
h^2_{pleio}/h^2 across the 15 target diseases was reduced by only 3% (s.e. 3%) and 1% (s.e. 3%)
when removing endocrine and mental disorder categories, respectively. These results imply that
pleiotropic heritability is broadly shared across disease categories, such that removal of one
disease category has a limited impact due to shared pleiotropic heritability with other disease
categories.

To investigate the impact of educational attainment (EA) on pleiotropic heritability, we
performed two analyses. First, we estimated h^2_{pleio}/h^2 with respect to EA (years of education)
as the only auxiliary trait. We determined that h^2_{pleio}/h^2 with respect to EA is 9.9% (s.e. 0.8%)
on average across 15 UK Biobank diseases (**Supplementary Figure 18** and **Supplementary
Table 28**). Second, we assessed the impact of removing EA from the set of auxiliary traits by
estimating the difference between (i) h^2_{pleio}/h^2 with respect to 15 UK Biobank auxiliary
diseases + 17 UK Biobank auxiliary quantitative traits vs. (ii) h^2_{pleio}/h^2 with respect to 15 UK
Biobank auxiliary diseases + 16 UK Biobank quantitative traits excluding EA. We determined
that the differences were small, with an average reduction of 0.87% (s.e. 0.39%)
(**Supplementary Figure 18** and **Supplementary Table 28**). This implies that the large
contribution of EA to pleiotropic heritability is mostly captured by other auxiliary traits.

We performed five secondary analyses. First, we investigated whether there is a correlation
between liability-scale heritability and h^2_{pleio}/h^2 across the 15 UK Biobank diseases. We
observed no significant correlation (correlation = -0.18 (P = 0.52); **Supplementary Figure 19**).
Second, we estimated the average h^2_{pleio}/h^2 across 15 UK Biobank diseases using different r_g^2
thresholds between target and auxiliary diseases (ranging from 0.1 to 0.8 in increments of 0.05)
(**Supplementary Figure 20** and **Supplementary Table 29**). Average h^2_{pleio}/h^2 increased at r_g^2
thresholds larger than 0.5, but we consider this increase to be not biologically meaningful
because most instances of $r_g^2 > 0.5$ involved auxiliary traits that *are not biologically distinct*
from the target trait, e.g. hypertension-diastolic blood pressure (r_g^2 = 0.72), hypertension-
systolic blood pressure (r_g^2 = 0.72), type 2 diabetes-glucose (r_g^2 = 0.69), type 2 diabetes-HbA1C

($r_g{}^2 = 0.79$). In addition, average $h^2{}_{pleio}/h^2$ decreased at $r_g{}^2$ thresholds smaller than 0.5, but all
instances of $0.25 < r_g{}^2 < 0.5$ involved auxiliary traits that *are biologically distinct* from the
target trait: coronary atherosclerosis-hypertension ($r_g{}^2 = 0.25$), coronary atherosclerosis-type 2
diabetes ($r_g{}^2 = 0.25$), hypertension-type 2 diabetes ($r_g{}^2 = 0.26$), depression-tobacco use disorder
($r_g{}^2 = 0.35$), gastroesophageal reflux disease (GERD)-tobacco use disorder ($r_g{}^2 = 0.27$), obesity-
type 2 diabetes ($r_g{}^2 = 0.36$), obesity-respiratory diseases ($r_g{}^2 = 0.29$), obesity- HbA1c ($r_g{}^2 =$
0.26), obesity-glucose ($r_g{}^2 = 0.26$), type 2 diabetes-body WHR ($r_g{}^2 = 0.36$), type 2 diabetes-BMI
($r_g{}^2 = 0.34$), type 2 diabetes-triglycerides ($r_g{}^2 = 0.31$), gastroesophageal reflux disease (GERD)-
depression ($r_g{}^2 = 0.40$), gastroesophageal reflux disease (GERD)-respiratory diseases ($r_g{}^2 =$
0.39) and depression-respiratory diseases ($r_g{}^2 = 0.32$). These findings support the use of an
estimand based on $r_g{}^2 < 0.5$ between target and auxiliary diseases/traits. Third, we compared
$h^2{}_{pleio}/h^2$ to the sum of (bias-corrected) $r_g{}^2$ across auxiliary diseases, across auxiliary disease
sets for a given target disease. For each of 15 UK Biobank target diseases, we considered 14
auxiliary disease sets (containing 1, …, 14 auxiliary diseases), starting with the auxiliary disease
with highest $r_g{}^2$ with the target disease and iteratively adding auxiliary diseases in the order of
decreasing $r_g{}^2$ with the target disease; we then computed the correlation between $h^2{}_{pleio}/h^2$ and
the sum of (bias-corrected) $r_g{}^2$ across the 14 auxiliary disease sets. The average correlation
(across 15 target diseases) was 0.28, implying that $h^2{}_{pleio}/h^2$ captures different information than
the sum of (bias-corrected) $r_g{}^2$ (**Supplementary Tables 30-31**). Fourth, we estimated genetic
correlations by applying BOLT-REML[31] to individual-data, instead of applying cross-trait
LDSC[8] to summary-level data. We determined that estimates of genetic correlation and
$h^2{}_{pleio}/h^2$ were broadly consistent (**Supplementary Figures 21-22**, **Supplementary Tables
20-21**). Fifth, we estimated genetic correlations using three modified versions of cross-trait
LDSC: constraining heritability intercept, constraining genetic covariance intercept, and
constraining both intercepts. We determined that all three modified versions deviated from
BOLT-REML results in estimates of genetic correlation and $h^2{}_{pleio}/h^2$ (**Supplementary
Figures 21-22**, **Supplementary Tables 20-21**), supporting our primary use of the default version
of cross-trait LDSC.

Application to 30 diseases from publicly available GWAS meta-analyses

We expanded our analyses to 30 highly heritable diseases with publicly available GWAS
summary statistics (heritability z-score > 6; observed-scale heritability under case-control
ascertainment ranging from 0.007 to 0.821 (with unknown prevalence); $r_g{}^2 < 0.5$; average
N=483K, spanning ten PheCode disease categories[33]) (**Supplementary Table 3**). These include
many diseases (e.g. autoimmune diseases and cancers) that were not included in the 15 diseases
in UK Biobank based on the criteria that we applied. For brevity, we subsequently refer to the
above 15 as 'UK Biobank' diseases and the 30 as 'non-UK Biobank' diseases (while duly noting
that a subset of the latter includes both non-UK Biobank and UK Biobank data). Genetic
correlations across these 30 diseases are reported in **Supplementary Figure 23** and
Supplementary Table 16. We again observed that most diseases have moderate genetic
correlations within disease categories and between disease categories; we note that it is not
feasible to estimate corresponding liability-scale phenotypic correlations in the absence of
individual-level data.

We first estimated h^2_{pleio}/h^2 for 15 UK Biobank target diseases with respect to different sets of auxiliary diseases. Results for three representative diseases (T2D, MDD, and HTN), and the average across 15 diseases, are reported in **Figure 6A**, **Supplementary Figure 24** and **Supplementary Table 22**. Average h^2_{pleio}/h^2 increased to 42% with respect to 30 non-UK Biobank auxiliary diseases (jackknife s.e.(avg) = 2%, s.d. = 27% across diseases), 44% with respect to all 45 UK Biobank + non-UK Biobank auxiliary diseases (jackknife s.e.(avg) = 5%, s.d. = 31% across diseases), and 49% (jackknife s.e. (avg) = 4%, s.d. = 28% across diseases) with respect to all 45 UK Biobank + non-UK Biobank auxiliary diseases and 17 UK Biobank quantitative traits, as compared to 27% with respect to 15 UK Biobank auxiliary diseases. Several diseases were dominated by pleiotropic heritability, including depression (74%, s.e. 7% w.r.t. all 62 auxiliary traits) and type 2 diabetes (59%, s.e. 4% w.r.t. all 62 auxiliary traits).

We next estimated h^2_{pleio}/h^2 for 30 non-UK Biobank target diseases with respect to different sets of auxiliary diseases. Results for three representative diseases (type 1 diabetes, attention-deficit/hyperactivity disorder, and asthma), and the average across 30 diseases, are reported in **Figure 6B**, **Supplementary Figure 25** and **Supplementary Table 23**. We observed a similar trend (increasing and then plateauing as the number of auxiliary traits increases) but with lower overall estimates: average h^2_{pleio}/h^2 increased to 31% with respect to 30 non-UK Biobank auxiliary diseases (jackknife s.e.(avg) = 1%, s.d. = 21% across diseases), 35% with respect to all 45 UK Biobank + non-UK Biobank auxiliary diseases (jackknife s.e.(avg) = 3%, s.d. = 23% across diseases), and 37% with respect to all 45 UK Biobank + non-UK Biobank auxiliary diseases and 17 UK Biobank auxiliary quantitative traits (jackknife s.e.(avg) = 2%, s.d. = 25% across diseases), as compared to 25% with respect to 15 UK Biobank auxiliary diseases.

Finally, we estimated h^2_{pleio}/h^2 of 15 UK Biobank target diseases or 30 non-UK Biobank target diseases with respect to auxiliary diseases in each of the 11 PheCode disease categories[33] spanned by all 45 UK Biobank + non-UK Biobank auxiliary diseases (analogous to **Figure 5**). Results are reported in **Supplementary Figure 26** and **Supplementary Table 24**. We again determined that auxiliary diseases from a single disease category often explain the majority of pleiotropic heritability (e.g. MDD had 68% (s.e. 8%) of SNP-heritability shared with other mental disorders), and that removing a single disease category from the set of auxiliary diseases reduced h^2_{pleio}/h^2 much less than the h^2_{pleio}/h^2 shared with that disease category (e.g. MDD h^2_{pleio}/h^2 was reduced by only 23% (s.e. 6%) when removing other mental disorders).

Comparing shared genetic and non-genetic variance

We sought to compare h^2_{pleio}/h^2 to the proportion of liability-scale total phenotypic variance of a target disease that is shared with a given set of auxiliary diseases (pleiotropic phenotypic variance, V^2_{pleio}; defined in **Methods**, analogous to Eq. 1, **Figure 1B**). We extended our method to estimate V^2_{pleio} by replacing genetic correlations (r_g) in Eq. 3 with liability-scale phenotypic correlations (r_l), estimated from individual-level data as in ref. 31(**Methods**). We determined via simulations that V^2_{pleio} estimates are unbiased without the need for bias correction, as r_l is accurately estimated at large sample sizes (**Supplementary Figure 27** and **Supplementary Table 25**). We used the ratio of pleiotropic phenotypic variance vs. total liability-scale phenotypic variance (V^2_{pleio}/V^2) to quantify the proportion of total liability-scale phenotypic

variance that is pleiotropic (noting that $V^2 = 1$ in standard parametrizations). Because estimating
r_l requires individual-level data, we analyzed 15 UK Biobank diseases only (**Table 1**).

A comparison of estimates of h^2_{pleio}/h^2 vs. V^2_{pleio}/V^2 is reported in **Figure 7** and
Supplementary Table 26; to ensure a fair comparison, we pruned the same auxiliary diseases in
estimates of V^2_{pleio}/V^2 as in our prior estimates of h^2_{pleio}/h^2. We determined that estimates of
h^2_{pleio}/h^2 were generally larger than estimates of V^2_{pleio}/V^2 (ratio of averages = 1.51x (s.e.
0.14)). h^2_{pleio}/h^2 was significantly larger than V^2_{pleio}/V^2 ($P < 0.05/15$) for 5 of 15 diseases,
including gastroesophageal reflux disease (GERD) (0.54 (s.e. 0.08) vs. 0.16 (s.e. 0.007)),
respiratory diseases (0.53 (s.e. 0.07) vs. 0.16 (s.e. 0.007)), obesity (0.49 (s.e. 0.06) vs. 0.20 (s.e.
0.006)), MDD (0.44 (s.e. 0.07) vs. 0.16 (s.e. 0.007)), and tobacco use disorder (0.36 (s.e. 0.07)
vs. 0.14 (s.e. 0.007)). Due to relatively small values of SNP-heritability, estimates of the
proportion of non-genetic variance that is shared with auxiliary diseases (E^2_{pleio}/E^2) were only
slightly smaller than V^2_{pleio}/V^2 estimates on average (**Supplementary Figure 29** and
Supplementary Table 26). We note that the difference between h^2_{pleio} and V^2_{pleio} also
includes heritability not captured by common SNPs, such as rare variant heritability, although we
expect that rare variant heritability is generally relatively small[40–42].

We performed a secondary analysis to investigate whether there is a correlation between
liability-scale heritability and the ratio of h^2_{pleio}/h^2 to V^2_{pleio}/V^2 across the 15 UK Biobank
diseases. We observed a negative correlation (correlation = -0.65, $P = 0.008$; **Supplementary**
Figure 32). The p-value of 0.008 is anti-conservative, as it treats the 15 diseases as independent
when they are in fact correlated, and it is thus unclear whether the correlation is statistically
significant.

Discussion

We have defined and estimated h^2_{pleio}, the genetic variance of a target disease that is shared
with a specific set of auxiliary diseases. We highlight four findings. First, bias correction had a
large impact on estimates of h^2_{pleio}. Second, roughly half of the total SNP-heritability of
common diseases is shared with other disease/traits. Third, the contribution of auxiliary diseases
to h^2_{pleio} is broadly distributed across disease categories, with h^2_{pleio} decreasing only slightly
when removing one auxiliary disease category. Finally, we compared h^2_{pleio}/h^2 to V^2_{pleio}/V^2
and determined that genetic variance is more strongly shared across diseases than environmental
variance; this finding could be explained by pleiotropic stabilizing selection on complex traits, in
which common variants with effects on multiple traits are preferentially retained[43].

We emphasize four downstream implications. First, our results can inform the incorporation of
genome-wide priors in polygenic risk scores that leverage pleiotropic diseases/traits[26,44–48].
Second, our work motivates the definition and estimation of *partitioned pleiotropic heritability*,
in which genetic values of auxiliary diseases/traits are partitioned into tissue/cell-type-specific
components[49–51], increasing shared genetic variance with the target disease and elucidating
shared biological processes[1–6,15,22,23]. Third, genetic values of auxiliary traits could also be
partitioned into gene pathways, elucidating shared biological pathways[52–54]. As such, our method
for pleiotropic heritability may be developed in further ways to inform risk prediction, drug

repurposing, prioritization of drug targets for multimorbid diseases, or improve the detection of
unintended drug side-effects. Finally, pleiotropic heritability could be applied to high-
dimensional auxiliary traits, such as brain imaging traits in studies of psychiatric disease[55,56].

We note several limitations of our work. First, jackknife standard errors on estimates of h^2_{pleio}
do not account for stochasticity that may in principle be introduced by pruning genetically
correlated auxiliary diseases to ensure numerical stability; however, we anticipate that the set of
pruned diseases would exhibit minimal variation across genomic jackknife blocks, due to limited
variation in genetic correlation estimates across blocks. Second, the definition of h^2_{pleio} is with
respect to a specific set of auxiliary traits, and results depends on the set of auxiliary traits;
however, the magnitude of the increase in h^2_{pleio}/h^2 plateaus as the number of auxiliary traits
increases (**Figure 6A** and **Figure 6B**), implying that expanding the set of auxiliary traits is
unlikely to increase the h^2_{pleio}/h^2 to the level of T2D and MDD for most other diseases; in
addition, removing disease categories from the set of auxiliary diseases does not reduce
h^2_{pleio}/h^2 much, implying that individual auxiliary diseases do not have a large impact on
h^2_{pleio}/h^2 when a sufficiently large set of auxiliary diseases are included. Third, genetic
correlation estimates include the effects of assortative mating, which can be substantial for some
diseases/traits[57] (e.g. educational attainment); our results do not distinguish between genetic
correlation due to shared causal effects vs. genetic correlation due to assortative mating, which
would require applying new methods to individual-level data[58]; however, we believe that cross-
trait assortative mating effects involving disease risk (e.g. with educational attainment) are likely
to be modest in most cases[57]. Fourth, definition and estimation of h^2_{pleio} is with respect to a
specific phenotype definition in a specific cohort. Ascertainment bias will carry through to our
definition and estimation of h^2_{pleio}; in particular, UK Biobank is known to be subject to
participation bias[59,60]. Phenotypic misclassification will also carry through to our definition and
estimation of h^2_{pleio}; we have restricted our analysis to individuals in UK Biobank with both
primary care data and hospital record data to limit the impact of phenotypic misclassification.
However, shared controls do not impact definition or estimation of h^2_{pleio}, because definition is
with respect to a population with infinite sample size and cross-trait LD score regression, which
we use to estimate genetic correlations, is robust to shared controls in a finite sample. Finally, we
restricted our analyses to individuals of European ancestry (represented in large sample size in
UK Biobank), but it is important to analyze more diverse cohorts[61,62], particularly for diseases
whose prevalence varies across populations. Despite these limitations, our definition and
estimation of h^2_{pleio} provide a robust quantification of the genetic variance of a target disease
that is shared with pleiotropic diseases/traits.

Code Availability

We have released open-source software implementing PHBC at
https://github.com/yjzhao1004/pleioh2g, and published on CRAN (https://cran.r-
project.org/web/packages/pleioh2g). Other publicly available software packages used in this
study are listed below: GWAS summary statistics were computed using PLINK2
(https://www.cog-genomics.org/plink/2.0/) and BOLT-LMM v2.4.1
(https://alkesgroup.broadinstitute.org/BOLT-LMM/downloads/), Heritability and genetic

correlation were estimated using LDSC (https://github.com/bulik/ldsc), the ldscr R package
(https://github.com/mglev1n/ldscr), and BOLT-REML as implemented in BOLT-LMM v 2.4.1.

Data Availability

473 Summary association statistics for all diseases/traits analyzed in this study have been made
474 publicly available at https://alkesgroup.broadinstitute.org/PHBC/.

Acknowledgements

Use of the UK Biobank data was performed under application number 19542. This research was
funded by Wellcome Trust early-career award 227566/Z/23/Z (X.J.) and NIH grants R01
HG006399, U01 HG012009, R01 MH101244, and R37 MH107649 (A.L.P.). M.I. is supported
by the Munz Chair of Cardiovascular Prediction and Prevention and the NIHR Cambridge
Biomedical Research Centre (NIHR203312) as well as by the UK Economic and Social
Research 878 Council (ES/T013192/1). J.D. is supported by a British Heart Foundation Personal
Chair. This work was supported by core funding from the British Heart Foundation
(RG/18/13/33946: RG/F/23/110103), NIHR Cambridge Biomedical Research Centre
(NIHR203312), BHF Chair Award (CH/12/2/29428), Cambridge BHF Centre of Research
Excellence (RE/24/130011, RE/18/1/34212) and by Health Data Research UK, which is funded
by the UK Medical Research Council, Engineering and Physical Sciences Research Council,
Economic and Social Research Council, Department of Health and Social Care (England), Chief
Scientist Office of the Scottish Government Health and Social Care Directorates, Health and
Social Care Research and Development Division (Welsh Government), Public Health Agency
(Northern Ireland), British Heart Foundation and the Wellcome Trust. The views expressed are
those of the authors and not necessarily those of the NIHR or the Department of Health and
Social Care. W.C. is supported by grants from the National Key R&D Program of China (No.
2023YFC3605400) and the National Natural Science Foundation of China (No. 82472055, No.
82071997).

496
497

Methods

Definition of h^2_{pleio}

We assume that the total liability of the target disease consists of genetic value (G) and environmental value (E). G of the target disease is divided into two components: private (disease-specific) genetic value ($G_{private}$) and pleiotropic genetic value (G_{pleio}), with the pleiotropic genetic value defined as a weighted linear combination of auxiliary disease genetic values (**Figure 1A**):

$$G_T = G_{private} + \sum_{j=1}^n \alpha_j G_j , \tag{4}$$

where α_j is the weight of the jth auxiliary disease (D_j), G_j is the genetic value of D_j, and G_T is the genetic value of target disease.

We define pleiotropic heritability as the maximum proportion of the total target disease heritability explained by the auxiliary diseases in the entire population. We use the ratio of pleiotropic heritability vs. total heritability ($\frac{h^2_{pleio}}{h^2}$) to quantify the proportion of genetic variance that is pleiotropic:

$$\frac{h^2_{pleio}}{h^2} = \max_{\alpha_j} \; r^2_{ind}\left[\sum_{j=1}^n \alpha_j G_j, \; G_T\right] \tag{5}$$

where r_{ind} denotes the correlation across individuals. We emphasize that h^2_{pleio} is a function of both the target disease and the selected set of auxiliary diseases/traits.

Analogously, we assume that standardized causal SNP effect sizes (number of standard deviation increase in phenotype per 1 standard deviation increase in genotype) on the target disease consist of two components: disease-specific effect sizes ($\beta_{disease-specific}$) and pleiotropic effect sizes (β_{pleio}), with the pleiotropic effect sizes defined as a weighted linear combination of auxiliary disease effect sizes:

$$\beta_T = \beta_{disease-specific} + \sum_{j=1}^n \alpha_j \beta_j , \tag{6}$$

where α_j is the weight for the jth auxiliary disease (D_j), β is the vector of additive causal SNP effect sizes ($\beta = (\beta_1, \beta_2, ..., \beta_m)$, where m denotes the number of SNPs), β_T is the vector of SNP effects on the target disease, and β_j is the vector of SNP effects on the jth auxiliary disease. In the general case that the genotype data does not include all causal SNPs, β are best-fit effect sizes obtained by projecting the phenotype onto the genotype space in the infinite population.

We restate the definition of equation (2):

$$h^2_{pleio}/h^2 = \max_{\alpha_j} r^2_{SNP}[\sum_{j=1}^n \alpha_j \beta_j, \beta_T] \tag{7}$$

where r_{SNP} denotes the correlation across SNPs. We note that equation (7) applies equally to
causal SNP effect sizes on either the liability or observed scale, as these effect sizes differ only
by a constant scaling factor, and the squared correlation r^2 is invariant under linear rescaling.

We note the definition in equation (1) and (2) are equivalent under the assumptions that

$$E\left[\beta_{T,i}\beta_{j,i'} \times LD(i,i')\right] = 0 \text{ for } i' \neq i, \tag{8}$$

where β denotes the causal SNP effect sizes defined under a random effect model, j is the
disease index (including the target disease), i, i' are SNP indices, and LD is the correlation
between genotypes. Intuitively, the assumption requires the causal effect sizes of SNPs that are
in LD with each other to be uncorrelated. We note that causal effect sizes for different SNPs
have been shown to have minimal correlations, particularly among common SNPs[63].

In detail, we model genetic value using standardized genotypes X and causal SNP-effect vector
β. The genetic value for the target disease is $G_T = X\beta_T$ and the weighted linear combination of
genetic value for n auxiliary disease is $\sum_{j=1}^n \alpha_j G_j = X(\sum_{j=1}^n \alpha_j \beta_j)$. Using the property of the
trace operator:

$$(X\beta_T)^T X\beta_T = Tr(X^T X\beta_T \beta_T^T) = \sum_{i \in SNPs} \sum_{i' \in SNPs} \{X^T X\}_{i,i'} \beta_{T,i} \beta_{T,i'}, \tag{9}$$

and

$$(X\beta_T)^T X(\sum_{j=1}^n \alpha_j \beta_j) = Tr\left(X^T X(\sum_{j=1}^n \alpha_j \beta_T \beta_j^T)\right) =$$
$$\sum_{i \in SNPs} \sum_{i' \in SNPs} \{X^T X\}_{i,i'} (\sum_{j=1}^n \alpha_j \beta_{T,i} \beta_{j,i'}). \tag{10}$$

Using the assumption of equation (8), $\sum_{i \neq i'} \{X^T X\}_{i,i'} \beta_{T,i} \beta_{T,i'} = 0$ and
$\sum_{i \neq i'} \{X^T X\}_{i,i'} (\sum_{j=1}^n \alpha_j \beta_{T,i} \beta_{j,i'}) = 0$ when the number of SNP goes to infinity, yielding:

$$(X\beta_T)^T X\beta_T = \sum_{i \in SNPs} \beta^2_{T,i} = \beta_T^T \beta_T, \tag{11}$$

and

$$(X\beta_T)^T X(\sum_{j=1}^n \alpha_j \beta_j) = \sum_{i \in SNPs}(\sum_{j=1}^n \alpha_j \beta_{T,i} \beta_{j,i}) = \beta_T^T (\sum_{j=1}^n \alpha_j \beta_j). \tag{12}$$

Therefore, the covariance between the target genetic value and weighted auxiliary disease
genetic value is

$$Cov\left(\sum_{j=1}^n \alpha_j G_j, G_T\right) = \sum_{j=1}^n \alpha_j \beta_j^T \beta_T \tag{13}$$

and the variances are $Var(\sum_{j=1}^n \alpha_j G_j) = \sum_{j,k} \alpha_j \alpha_k \beta_j^T \beta_k \tag{14}$

559 and $Var(G_T) = \beta_T^T \beta_T$.   (15)

560 Therefore, the squared correlation of genetic value across individuals (r_{ind}^2) in a population of
561 infinite sample size equals the squared correlation across SNPs (r_{SNP}^2):

562 $r_{ind}^2\left(\sum_{j=1}^n \alpha_j G_j, G_T\right) = r_{SNP}^2\left(\sum_{j=1}^n \alpha_j \beta_j, \beta_T\right)$   (16)

564 *Initial estimate of $h^2{}_{pleio}$*

565 We employ pleiotropic heritability with bias correction (PHBC) to obtain an unbiased estimate
566 of $\frac{h_{pleio}^2}{h^2}$ with finite sample sizes.

567 According to the definition in equation (7), pleiotropic heritability is not changed when
568 multiplying $\boldsymbol{\alpha}$ by a non-zero scaling factor. We note that the quantity in equation (7) is
569 equivalent to regression $\boldsymbol{R^2}$, therefore we change the optimization to:

570 $\frac{h_{pleio}^2}{h^2} = \max_{\alpha_j} \left[R_{regression\ across\ SNPs}^2\left(\beta_T \sim \sum_{j=1}^n \alpha_j \beta_j\right)\right]$   (17)

571 so that the α_j are identifiable. We derive the expression of h_{pleio}^2 as follows:

572 Let $\boldsymbol{\alpha}^*$ be the estimated $\boldsymbol{\alpha}$ that maximizes the right-hand side of equation (17).

573 Let $\boldsymbol{C}_{DD}$ be the $n \times n$ covariance matrix of $\{\beta_j\}_{j=1}^n$

574 Let $\boldsymbol{c}_{TD}$ be the $n \times 1$ covariance vector between β_T and $\{\beta_j\}_{j=1}^n$

575 Under the assumption of equation (8), the variance of pleiotropic genetic value $X\sum_{j=1}^n \alpha_j \beta_j$ is:

576 $Var\left[X\sum_{j=1}^n \alpha_j \beta_j\right] = m \times \sum_{i=1}^n \sum_{j=1}^n \alpha_i \alpha_j Cov(\beta_i, \beta_j) = m \times \boldsymbol{\alpha}^T \boldsymbol{C}_{DD} \boldsymbol{\alpha}$   (18)

577 To estimate $h^2{}_{pleio}$, we first estimate the $\boldsymbol{\alpha}^*$ by minimizing the squared error between β_T and
578 $\sum_{j=1}^n \alpha_j \beta_j$: $\left(\beta_T - \sum_{j=1}^n \alpha_j \beta_j\right)^T \left(\beta_T - \sum_{j=1}^n \alpha_j \beta_j\right)$ (which is equivalent to maximizing regression
579 $\boldsymbol{R^2}$). The parameters are estimated across all SNPs which is sufficiently large that prevents
580 overfitting. By taking the partial derivative of $\left(\beta_T - \sum_{j=1}^n \alpha_j \beta_j\right)^T \left(\beta_T - \sum_{j=1}^n \alpha_j \beta_j\right)$ with respect
581 to $\boldsymbol{\alpha}$:

582 $\frac{\partial}{\partial \alpha}\left(\beta_T - \sum_{j=1}^n \alpha_j \beta_j\right)^T \left(\beta_T - \sum_{j=1}^n \alpha_j \beta_j\right)$

583 $= \frac{\partial}{\partial \alpha}\left(\beta_T^T \beta_T - 2\sum_{j=1}^n \alpha_j \beta_T^T \beta_j + \left(\sum_{j=1}^n \alpha_j \beta_j\right)^T \left(\sum_{j=1}^n \alpha_j \beta_j\right)\right)$

$\quad = m \times \frac{\partial}{\partial \boldsymbol{\alpha}}(h_T^2/m - 2\boldsymbol{\alpha}^T \boldsymbol{c}_{TD} + \boldsymbol{\alpha}^T \boldsymbol{C}_{DD}\boldsymbol{\alpha})$

$\quad = m(-2\boldsymbol{c}_{TD} + (\boldsymbol{C}_{DD} + \boldsymbol{C}_{DD}^T)\boldsymbol{\alpha}),$ $\hspace{5cm}$ (19)

where m is the number of SNPs, the expectation of each SNP effect is 0. By setting the partial
derivative to zero, we can obtain the optimal weight vector for each SNP:

$\quad \boldsymbol{C}_{DD}\boldsymbol{\alpha}^* = \boldsymbol{c}_{TD}$ $\hspace{7cm}$ (20)

If $\boldsymbol{C}_{DD}$ is invertible, the optimal $\boldsymbol{\alpha}^*$ is:

$\quad \boldsymbol{\alpha}^* = \boldsymbol{C}_{DD}^{-1}\boldsymbol{c}_{TD}$ $\hspace{6cm}$ (21)

After substituting the $\boldsymbol{\alpha}^*$ into equation (18):

$\quad h^2{}_{pleio} = m \times \boldsymbol{c}_{TD}^T \boldsymbol{C}_{DD}^{-1} \boldsymbol{c}_{TD}$ $\hspace{5cm}$ (22)

Elements in $\boldsymbol{c}_{TD}$ and $\boldsymbol{C}_{DD}$ denote per-SNP heritability and genetic covariance; in this study we
focus on SNP-heritability and genetic correlation between causal SNP effect sizes. Let h_T^2 be the
heritability of the target disease. $\boldsymbol{h}_D^2 = \left\{h_j^2\right\}_{j=1}^n$ is the vector consisting of the heritability of all
auxiliary diseases. $r_g[\boldsymbol{D}, T]$ is the genetic correlation vector between the target disease and all
auxiliary diseases, $r_g[\boldsymbol{D}, \boldsymbol{D}]^{-1}$ is the inverse of genetic correlation matrix of all auxiliary
diseases. diag(.) is diagonal matrix with all non-diagonal elements equal to zero.

$\quad \boldsymbol{c}_{TD} = diag\left(\sqrt{\frac{h_T^2}{m}}\left(\sqrt{\frac{h_D^2}{m}}\right)^T\right)r_g[\boldsymbol{D}, T]$ $\hspace{3cm}$ (23)

$\quad \boldsymbol{C}_{DD}^{-1} = diag\left(1/\sqrt{\frac{h_D^2}{m}}\right)r_g[\boldsymbol{D}, \boldsymbol{D}]^{-1}diag\left(1/\sqrt{\frac{h_D^2}{m}}\right)$ $\hspace{1.5cm}$ (24)

After substituting equation (23) and (24) into equation (22), $h^2{}_{pleio}$ can be expressed as:

$\quad h^2{}_{pleio} = h_T^2 \times r_g[\boldsymbol{D}, T]^T r_g[\boldsymbol{D}, \boldsymbol{D}]^{-1} r_g[\boldsymbol{D}, T]$ $\hspace{3cm}$ (25)

$\quad \frac{h^2{}_{pleio}}{h^2} = r_g[\boldsymbol{D}, T]^T r_g[\boldsymbol{D}, \boldsymbol{D}]^{-1} r_g[\boldsymbol{D}, T]$ $\hspace{3.5cm}$ (26)

Equation (26) provides the initial pleiotropic heritability estimates, prior to bias correction
described in the next section. In this study, we used GWAS summary statistics as input and
reimplemented cross-trait LDSC[8] so that the standard errors of all quantities on the right-hand
side of equation (26) are estimated through the same genomic jackknife blocks. We used 1000
Genomes Project[64] Europeans as a reference LD panel to estimate genetic correlation. Standard
error estimates were obtained via genomic block-jackknife with 200 blocks applied across all
traits, which were created by partitioning 1,217,311 HapMap 3 SNPs[36]. We primarily focus on
$h^2{}_{pleio}/h^2$ estimates (instead of $h^2{}_{pleio}$ estimates) throughout the manuscript.

Monte Carlo bias correction to initial estimate of h^2_{pleio}

The initial estimates $\left(\frac{h^2_{pleio}}{h^2}\right)_{initial}$ are based on estimates of genetic correlation in finite GWAS

sample size, which introduces an upward bias in estimating $\frac{h^2_{pleio}}{h^2}$ due to inverting the estimated

genetic correlation matrix and sampling correlation between $r_g[\boldsymbol{D},T]^T$, $r_g[\boldsymbol{D},\boldsymbol{D}]^{-1}$, and $r_g[\boldsymbol{D},T]$

in equation (26):

$$\left(\frac{h^2_{pleio}}{h^2}\right)_{initial} > \left(\frac{h^2_{pleio}}{h^2}\right)_{true} \tag{27}$$

Specifically, if only one auxiliary disease is included, h^2_{pleio}/h^2 will be equivalent to r_g^2; the

expectation of the squared genetic correlation estimates $E[\widehat{r_g^2}] = r_g^2 + \left(s.e.\left(\widehat{r_g}\right)\right)^2$ will be larger

than the square of true genetic correlation r_g^2, indicating an upward bias in h^2_{pleio}/h^2. If

multiple auxiliary diseases are included, the expectation of Eq. 3 is upward biased for noisy

$r_g\widehat{[\boldsymbol{D},T]}$ when $r_g[\boldsymbol{D},\boldsymbol{D}]^{-1}$ is positive definite: $E[r_g\widehat{[\boldsymbol{D},T]}^T r_g[\boldsymbol{D},\boldsymbol{D}]^{-1} r_g\widehat{[\boldsymbol{D},T]}] =$

$r_g[\boldsymbol{D},T]^T r_g[\boldsymbol{D},\boldsymbol{D}]^{-1} r_g[\boldsymbol{D},T] + E[\epsilon(r_g[\boldsymbol{D},T])^T r_g[\boldsymbol{D},\boldsymbol{D}]^{-1} \epsilon(r_g[\boldsymbol{D},T])]$, where $\epsilon(r_g[\boldsymbol{D},T])$ is the

estimation error of $r_g\widehat{[\boldsymbol{D},T]}$; we used $E[r_g\widehat{[\boldsymbol{D},T]}] = r_g[\boldsymbol{D},T]$. Since $r_g[\boldsymbol{D},\boldsymbol{D}]^{-1}$ is the estimate of

the inverse of a genetic correlation matrix which is positive semi-definite, it is likely positive

semi-definite. Therefore, the second term in this equation is non-negative, likely causing an

upward bias in our initial estimate of h^2_{pleio}/h^2 in Eq. 3.

To obtain an unbiased estimate, we employ a Monte-Carlo bias correction procedure to estimate

the proportion of bias in the point estimate of $\frac{h^2_{pleio}}{h^2}$ and then correct the bias. First, we generate

Monte-Carlo samples of the estimation error ϵ_i in the genetic correlation matrix from the

sampling covariance matrix[17] generated from genomic block-jackknife; if the dimension of the

genetic correlation matrix is $n \times n$, the sampling covariance matrix is a symmetric matrix with

dimension $n(n\text{-}1)/2 \times n(n\text{-}1)/2$, which captures the joint distribution across estimation errors of

different elements in $r_g[\boldsymbol{D},T]$ and $r_g[\boldsymbol{D},\boldsymbol{D}]$. Second, we add the estimation noise to the point

estimate of genetic correlation matrix to create Monte-Carlo samples of estimated $r_g[\boldsymbol{D},T]$ and

$r_g[\boldsymbol{D},\boldsymbol{D}]^{-1}$. We filter these Monte-Carlo samples to only keep those whose $r_g[\boldsymbol{D},\boldsymbol{D}]$ are non-

singular (i.e. the smallest eigenvalue of $r_g[\boldsymbol{D},\boldsymbol{D}]$ is larger than 0). We repeat this Monte-Carlo

procedure until we have generated 1,000 samples of genetic correlation estimates.

Using these Monte-Carlo samples, we next estimate a scaling coefficient ξ_c so that:

$$Avg_i[(\xi_c r_g[\boldsymbol{D},T] + \epsilon_i[\boldsymbol{D},T])^T (r_g[\boldsymbol{D},\boldsymbol{D}] + \epsilon_i[\boldsymbol{D},\boldsymbol{D}])^{-1}(\xi_c r_g[\boldsymbol{D},T] + \epsilon_i[\boldsymbol{D},T])] = \left(\frac{h^2_{pleio}}{h^2}\right)_{initial}$$

$$\tag{28}$$

The left-hand side is the average across Monte-Carlo samples, ϵ_i are the respective Monte-Carlo

samples of estimation errors for $r_g[\boldsymbol{D},T]$ and $r_g[\boldsymbol{D},\boldsymbol{D}]$, where i indexes Monte-Carlo samples.

The above equation is based on the heuristic that the magnitude of pleiotropic heritability is
proportional to the average genetic correlation between target disease and auxiliary diseases
$r_g[\boldsymbol{D}, T]$. Downward scaling $r_g[\boldsymbol{D}, T]$ will downward scale $\frac{h^2{}_{pleio}}{h^2}$, which controls the upward
bias in equation (27). On the other hand, $r_g[\boldsymbol{D}, \boldsymbol{D}]$ are between pairs of auxiliary diseases which
is not directly connected to the scale of $\frac{h^2{}_{pleio}}{h^2}$. The error term ϵ_i is not multiplied by ξ_c as
estimation error for genetic correlation is a function of sample size and the heritability, which is
not proportional to the scale of the point estimate of genetic correlation.

We estimate scaling coefficient ξ_c using binary search on the interval [0,1], in order to satisfy
equation (28). We multiply the initial estimate $\left(\frac{h^2_{pleio}}{h^2}\right)_{initial}$ and its standard error by ξ_c^2 to obtain
the bias-corrected estimate of $h^2{}_{pleio}/h^2$ and its standard error.

Pruning auxiliary diseases with high genetic correlation

In the presence of collinearity among auxiliary diseases and large uncertainty in genetic
correlation estimates, the estimator in equation (26) can be numerically unstable, which we
define as (1) The pre-correction jackknife standard error of $\frac{h^2_{pleio}}{h^2}$ with respect to the pre-pruning
auxiliary disease sets is greater than 0.5, and/or (2) the scaling coefficient ξ_c is less than 0.5
(implying that >75% of the initial $\frac{h^2_{pleio}}{h^2}$ estimate is due to uncertainty in genetic correlation
matrix estimates). We also apply the pruning procedure if (3) it takes more than 50 iterations to
sample a non-singular $r_g[\boldsymbol{D}, \boldsymbol{D}]$ in the Monte-Carlo sampling of bias correction, which indicates
that the collinearity of auxiliary diseases causes singularity in samples of $r_g[\boldsymbol{D}, \boldsymbol{D}]$.

To apply the pruning procedure, we prune the auxiliary diseases by progressively applying
stricter r_g^2 thresholds between the auxiliary diseases: 0.5, 0.4, 0.3, 0.2, and 0.1. For each
r_g^2 threshold, when a pair of auxiliary diseases has r_g^2 above the threshold, we keep the disease
with larger r_g z-score with the target disease. We repeat this pruning step until all three criteria
no longer hold, and we report the $\frac{h^2{}_{pleio}}{h^2}$ estimate from the pruned set of auxiliary diseases.

Pleiotropic phenotypic variance

To compare $h^2{}_{pleio}/h^2$ with the non-genetic variance that can be explained by the same set of
auxiliary diseases, we extend our method to estimate pleiotropic phenotypic variance ($V^2{}_{pleio}$),
defined as the proportion of phenotypic variance of target disease liability (σ_T) that can be
explained by any linear combination of liabilities of auxiliary disease (σ_D) (**Figure 1B**).

We convert the observed-scale phenotypic correlation to liability-scale phenotypic correlation r_l
using Monte-Carlo simulations[31] under the liability threshold model[65]. To model the relationship

between liability-scale correlation r_l and observed-scale correlations r_o for two binary traits with
different prevalences, we simulate liabilities using r_l on a grid between -1 to 1. For each r_l, we
simulate pairs of disease liabilities from a multivariate normal distribution with covariance equal
to specified r_l, and then use liability threshold model to create the binary disease status by
thresholding the liabilities based on their respective prevalences. We then calculate the r_o
between the simulated binary traits. This process generates a map between r_l and r_o for two
disease traits of given prevalences. Using this mapping, we can map the observed r_o for the 15
UK Biobank diseases to obtain the corresponding r_l. We use the r_l matrix to estimate $V^2{}_{pleio}$ in
the same way as pleiotropic heritability:

$V^2{}_{pleio} = 1 \times r_l[\boldsymbol{\sigma_D}, \sigma_T]^T r_l[\boldsymbol{\sigma_D}, \boldsymbol{\sigma_D}]^{-1} r_l[\boldsymbol{\sigma_D}, \sigma_T]$ (29)

where 1 is the total liability variance for the target disease, $r_l[\boldsymbol{\sigma_D}, \sigma_T]$ is the liability-scale
phenotypic correlation matrix between target disease and auxiliary diseases, $r_l[\boldsymbol{\sigma_D}, \boldsymbol{\sigma_D}]^{-1}$ is the
inverse of liability-scale phenotypic correlation among auxiliary diseases. We estimate the
standard error of r_l and $V^2{}_{pleio}$ by jackknifing over 1000 blocks of individuals across all
diseases. We also compare the difference between r_g and r_l with Bonferroni-corrected significant
threshold set at $P < 4.76 \times 10^{-4}$ (0.05/105, where 105 is the number of pairs of the 15 diseases)
(**Figure 3** and **Supplementary Table 15**).

We compare three quantities: (1) $\frac{h^2{}_{pleio}}{h^2}$, the proportion of genetic variance that is pleiotropic; (2)

$\frac{V^2{}_{pleio}}{V^2}$, the proportion of liability variance that is shared with the set of auxiliary diseases, and (3)

$\frac{E^2{}_{pleio}}{E^2}$, the proportion of non-genetic variance (including rare variant heritability and
environmental variance) that is shared with the set of auxiliary diseases, calculated as:

$\frac{E^2{}_{pleio}}{E^2} = \frac{V^2{}_{pleio} - h^2{}_{pleio}}{V^2 - h^2}$ (30)

We computed the ratios between $\frac{h^2{}_{pleio}}{h^2}$ vs. $\frac{V^2{}_{pleio}}{V^2}$, $\frac{E^2{}_{pleio}}{E^2}$ vs. $\frac{V^2{}_{pleio}}{V^2}$, $h^2{}_{pleio}$ vs. $V^2{}_{pleio}$, and

$\frac{h^2{}_{pleio}}{h^2}$ vs. $\frac{E^2{}_{pleio}}{E^2}$. Full results are listed in **Supplementary Figures 28-31** and **Supplementary**
Table 26.

Simulations

We performed simulation using real UK Biobank genotypes from 1,122,329 HapMap3[36] SNPs
across 157,206 unrelated individuals (see below). We simulated 16 diseases with liability-scale
heritabilities equal to 0.13 (median of 15 UK Biobank diseases) and prevalences equal to 0.1
(median of 15 UK Biobank diseases); we have also included simulations with heritability z-
scores matching the median value of 15 UK Biobank diseases (**Supplementary Figure 8** and
Supplementary Figure 10). True genetic correlations were set to 0.5 within diseases categories
and 0.1 between diseases categories for the first 15 diseases (based on the 7 PheCode disease
categories from **Table 1**) and 0.0 for the 16th disease (with all other 15 diseases), which results

in 5 different values of true $\frac{h^2_{pleio}}{h^2}$. The proportion of causal SNPs was set to 5% in the primary

simulations (and 1% in a secondary simulation). For each simulation, we first simulated the

causal effect sizes using infinitesimal model based on the specified heritability and genetic

correlation. Then, we used PLINK2[37] to compute genetic values (which sum over

causal_effect_size × causal_allele_dosage) for 157,206 unrelated individuals and added

environmental noise to generate the individual liabilities for the 16 diseases. We used the

liability threshold model to generate binary phenotype based on the specified prevalence and

computed GWAS summary statistics using PLINK2[37]. We applied cross-trait LDSC[8] to the

GWAS summary statistics for the 1,121,509 SNPs (MAF > 0.01) and used reference LD from

1000 Genomes Europeans individuals (9,254,535 SNPs) to estimate genetic correlations. We

applied PHBC to estimate $\frac{h^2_{pleio}}{h^2}$ and compared it with the true value. We also compared the

squared genomic-jackknife standard error of $\frac{h^2_{pleio}}{h^2}$ with the squared deviation (defined as the

squared difference between the estimated post-corrected $\frac{h^2_{pleio}}{h^2}$ and true value) to investigate

whether the reported standard errors were well-calibrated.

We also performed a simulation to validate V^2_{pleio} estimation. True r_o was set to 0.5 within

diseases categories and 0.1 between diseases categories for the 15 diseases (based on the 7

PheCode disease categories). We simulated liabilities for 228,258 individuals (see below). We

computed true r_l and true V^2_{pleio} based on the simulated liabilities. Then, we used the liability

threshold model to generate binary phenotypes based on the empirical prevalences of the 15 UK

Biobank diseases. We applied our method to the simulated binary phenotypes to estimate V^2_{pleio}

and compared it to the true value.

UK Biobank data

For disease phenotype pre-processing, we collected diagnoses from both inpatient data and

primary care data. An individual is defined as a case if there is a diagnosis from either inpatient

data or primary care data. We selected 228,258 samples with both primary care and hospital

inpatient records. Diagnoses from hospital inpatient records were obtained from Hospital

Episode Statistics (HES) for England, which are recorded as the International Classification of

Diseases (ICD-10) system codes. Diagnoses from primary care data were retrieved from a subset

of UK Biobank samples (see below), which are recorded in Read Codes v.2 (Read v.2) and Read

Codes Clinical Terms v.3 (Read CTv.3). We mapped primary care data from Read v.2 to ICD-10

codes, and combine with the ICD-10codes from HES data. We kept ICD-10 codes starting with

the letters A to N which are disease codes. Then, we mapped the ICD-10 records to PheCode

system to obtain the phenotype definition[33,66] and selected the PheCode phenotypes with > 1%

prevalence in the 228,258 samples.

We selected 15 relatively independent heritable diseases with heritability *z*-scores larger than 6

(heritabilities were computed using cross-trait LDSC[8]), which are distributed across 7 PheCode

disease categories. We note that we did not include any UK Biobank autoimmune diseases or

cancers, because they did not meet our criteria of prevalence > 1% and heritability z-score > 6.

We used 228,258 samples to compute pleiotropic phenotypic variance across these 15 UK Biobank disease phenotypes. Detailed information on phenotype codes, prevalences, and categories are listed in **Table 1**.

We selected 157,206 unrelated (defined as having less than 11 putative third-degree relatives in the kinship table) British ancestry individuals from the 228,258 samples to compute GWAS summary statistics for 15 UK Biobank diseases, where we used 1,141,346 HapMap 3 SNPs (see below; 1,117,934 of them overlap with the SNPs used in simulations)[36].We used BOLT-LMM[67,68] to compute summary statistics. Since BOLT-LMM test statistics are well-calibrated for traits with a case fraction of at least 10%[68], for diseases with prevalence lower than 10% we matched each case with a subset of nine randomly sampled controls, to avoid miscalibration in unbalanced case-control samples.

Detailed genotyping and quality control procedures in the UK Biobank are described previously[32]. We excluded SNPs with call rates of < 95%, minor allele frequency of < 0.1%, deviation from the Hardy–Weinberg equilibrium with $P < 1 \times 10^{-10}$. We then generated the PLINK-format data for BOLT-LMM using two steps: 1) subset to the 157,206 unrelated British individuals with genotype data; 2) subset the SNPs to HapMap3 SNPs and using PLINK2 to LD prune at $r^2<0.8$ to obtain the set of relatively independent SNPs (PLINK2 command "-indep-pairwise 50 5 0.8"). 470,851 SNPs from 157,206 samples remained after the pruning step, and were carried forward to BOLT-REML for variance components analysis; we reused the full 1,141,346 HapMap 3 SNPs to compute the BOLT-LMM association test statistics.

We selected 17 quantitative traits for relevance to disease from ref. 34,35 for the same set of individuals (Average $N = 230$K) and corrected for medication use, as follows. We corrected blood biochemistry measurements for cholesterol, hypertensive, and diabetic medications: total cholesterol, LDL, and triglyceride levels were corrected for lipid lowering medications[69]; systolic blood pressure and diastolic blood pressure were corrected for hypertension medications[70]; and HbA1c level was corrected for non-insulin diabetic medications and insulin drugs . We verified that the correlation between the corrected quantitative traits and corresponding binary traits was higher compared to uncorrected quantitative traits. We also included educational attainment (years of education) to evaluate the impact of socio-economic status. Detailed information on trait names, categories, heritability estimates and genetic correlation estimates for these 17 quantitative traits is provided in **Supplementary Tables 2** and **16**.

GWAS summary statistics for 30 diseases from publicly available GWAS meta-analyses

We collected publicly available GWAS summary statistics for 30 relatively independent heritable diseases under the same criteria (heritability z-score > 6 and $r_g^2 < 0.5$) that are primarily from European ancestry. We note that some of these 30 publicly available disease summary statistics are meta-analyses that include UK Biobank samples. The 30 diseases are assigned to 10 PheCode categories[33]. Details of phenotype information, heritability, and genetic correlation estimates from cross-trait LDSC for these 30 diseases are reported in **Supplementary Tables 3** and **16**.

Analyses with one or more disease categories excluded from the set of auxiliary diseases

We performed leave-category-out analyses to investigate the change in $\frac{h^2{}_{pleio}}{h^2}$ when removing

PheCode Categories. First, we estimated the $\frac{h^2{}_{pleio}}{h^2}$ with respect to three auxiliary disease sets: 1)

all auxiliary diseases; 2) all diseases excluding the auxiliary diseases in the target disease
category; 3) all diseases excluding the auxiliary diseases in target disease category and one other
category. We implemented leave-category-out analyses in the PHBC software.

To evaluate the contribution of a single PheCode category to $\frac{h^2{}_{pleio}}{h^2}$, we computed the reduction

of $\frac{h^2{}_{pleio}}{h^2}$ when removing the auxiliary PheCode category. To remove the impact of randomness

in Monte-Carlo bias correction when computing the reduction, we first computed the difference

of $\frac{h^2{}_{pleio}}{h^2}$ with respect to all auxiliary diseases vs. $\frac{h^2{}_{pleio}}{h^2}$ with respect to auxiliary diseases

excluding a PheCode category before bias correction. We multiplied the difference by the scaling

coefficient ξ_c^2 of $\frac{h^2{}_{pleio}}{h^2}$ with respect to all auxiliary diseases, which represented the contribution

of an auxiliary PheCode category to the $\frac{h^2{}_{pleio}}{h^2}$ with respect to all auxiliary diseases. We reported

the jackknife standard error of the before-bias-correction difference of $\frac{h^2{}_{pleio}}{h^2}$ as the standard

error of the reduction, which is a conservative standard error shown by simulations
(**Supplementary Figure 14** and **Supplementary Table 13**).

Alternative approaches for estimating r_g

To validate the r_g estimated from cross-trait LDSC without constrained intercept, we used
BOLT-REML and cross-trait LDSC using constrained intercept to estimate r_g. We applied
BOLT-REML to individual-data using 470,851 SNPs across 157,206 unrelated individuals of
British ancestry to estimate r_g among these 15 UK Biobank diseases. We constrained heritability
intercept in cross-trait LDSC to be 1. We also computed the analytical intercept for genetic
covariance considering sample overlap for each disease pair using equation 16 in the
Supplementary Note of ref. 8. The constrained intercepts for genetic covariance for each disease
pair are provided in **Supplementary Table 27**.
820
821

References

1. Cotsapas, C. *et al.* Pervasive Sharing of Genetic Effects in Autoimmune Disease. *PLoS*

Genet **7**, e1002254 (2011).

2. Solovieff, N., Cotsapas, C., Lee, P. H., Purcell, S. M. & Smoller, J. W. Pleiotropy in complex

traits: challenges and strategies. *Nat Rev Genet* **14**, 483–495 (2013).

3. Watanabe, K. *et al.* A global overview of pleiotropy and genetic architecture in complex

traits. *Nat Genet* **51**, 1339–1348 (2019).

4. Lee, P. H. *et al.* Genomic Relationships, Novel Loci, and Pleiotropic Mechanisms across

Eight Psychiatric Disorders. *Cell* **179**, 1469-1482.e11 (2019).

5. Zhao, B. *et al.* Heart-brain connections: Phenotypic and genetic insights from magnetic

resonance images. *Science* **380**, abn6598 (2023).

6. Mackay, T. F. C. & Anholt, R. R. H. Pleiotropy, epistasis and the genetic architecture of

quantitative traits. *Nat Rev Genet* **25**, 639–657 (2024).

7. Cross-Disorder Group of the Psychiatric Genomics Consortium. Genetic relationship

between five psychiatric disorders estimated from genome-wide SNPs. *Nat Genet* **45**, 984–

994 (2013).

8. Bulik-Sullivan, B. *et al.* An atlas of genetic correlations across human diseases and traits. *Nat*

Genet **47**, 1236–1241 (2015).

9. Pickrell, J. K. *et al.* Detection and interpretation of shared genetic influences on 42 human

traits. *Nat Genet* **48**, 709–717 (2016).

10. Anttila, V. *et al.* Analysis of shared heritability in common disorders of the brain. *Science*

360, (2018).

11. O'Connor, L. J. & Price, A. L. Distinguishing genetic correlation from causation across 52

diseases and complex traits. *Nat Genet* **50**, 1728–1734 (2018).

12. Morrison, J., Knoblauch, N., Marcus, J. H., Stephens, M. & He, X. Mendelian randomization

accounting for correlated and uncorrelated pleiotropic effects using genome-wide summary

statistics. *Nat Genet* **52**, 740–747 (2020).

13. Demange, P. A. *et al.* Investigating the genetic architecture of noncognitive skills using

GWAS-by-subtraction. *Nat Genet* **53**, 35–44 (2021).

14. Wu, Y. *et al.* Fast estimation of genetic correlation for biobank-scale data. *The American*

Journal of Human Genetics **109**, 24–32 (2022).

15. Udler, M. S. *et al.* Type 2 diabetes genetic loci informed by multi-trait associations point to

disease mechanisms and subtypes: A soft clustering analysis. *PLoS Med* **15**, e1002654

(2018).

16. Tanigawa, Y. *et al.* Components of genetic associations across 2,138 phenotypes in the UK

Biobank highlight adipocyte biology. *Nat Commun* **10**, (2019).

17. Grotzinger, A. D. *et al.* Genomic structural equation modelling provides insights into the

multivariate genetic architecture of complex traits. *Nat Hum Behav* **3**, 513–525 (2019).

18. Sakaue, S. *et al.* A cross-population atlas of genetic associations for 220 human phenotypes.

Nat Genet **53**, 1415–1424 (2021).

19. Grotzinger, A. D. *et al.* Genetic architecture of 11 major psychiatric disorders at

biobehavioral, functional genomic and molecular genetic levels of analysis. *Nat Genet* **54**,

548–559 (2022).

20. Ballard, J. L. & O'Connor, L. J. Shared components of heritability across genetically

correlated traits. *The American Journal of Human Genetics* **109**, 989–1006 (2022).

21. Zhang, Z. *et al.* A scalable approach to characterize pleiotropy across thousands of human

diseases and complex traits using GWAS summary statistics. *The American Journal of*

Human Genetics **110**, 1863–1874 (2023).

22. Suzuki, K. *et al.* Genetic drivers of heterogeneity in type 2 diabetes pathophysiology. *Nature*

627, 347–357 (2024).

23. Smith, K. *et al.* Multi-ancestry polygenic mechanisms of type 2 diabetes. *Nat Med* **30**, 1065–

1074 (2024).

24. Nieuwboer, H. A., Pool, R., Dolan, C. V., Boomsma, D. I. & Nivard, M. G. GWIS: Genome-

Wide Inferred Statistics for Functions of Multiple Phenotypes. *The American Journal of*

Human Genetics **99**, 917–927 (2016).

25. Dahl, A. *et al.* A multiple-phenotype imputation method for genetic studies. *Nat Genet* **48**,

466–472 (2016).

26. Turley, P. *et al.* Multi-trait analysis of genome-wide association summary statistics using

MTAG. *Nat Genet* **50**, 229–237 (2018).

27. Baselmans, B. M. L. *et al.* Multivariate genome-wide analyses of the well-being spectrum.

Nat Genet **51**, 445–451 (2019).

28. Dahl, A. *et al.* Phenotype integration improves power and preserves specificity in biobank-

based genetic studies of major depressive disorder. *Nat Genet* **55**, 2082–2093 (2023).

29. Zhou, F., Astle, W. J., Butterworth, A. S. & Asimit, J. L. Improved genetic discovery and

fine-mapping resolution through multivariate latent factor analysis of high-dimensional

traits. *Cell Genomics* **5**, 100847 (2025).

30. Tibshirani, R. J. & Efron, B. An introduction to the bootstrap. *Monographs on statistics and*

applied probability **57**, 1–436 (1993).

31. Loh, P.-R. *et al.* Contrasting genetic architectures of schizophrenia and other complex

diseases using fast variance-components analysis. *Nat Genet* **47**, 1385–1392 (2015).

32. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data.

Nature **562**, 203–209 (2018).

33. Bastarache, L. Using Phecodes for Research with the Electronic Health Record: From

PheWAS to PheRS. *Annu. Rev. Biomed. Data Sci.* **4**, 1–19 (2021).

34. Weissbrod, O. *et al.* Functionally informed fine-mapping and polygenic localization of

complex trait heritability. *Nat Genet* **52**, 1355–1363 (2020).

35. Jiang, X. *et al.* Exposure accumulation drives age-dependent disease architectures and

polygenic risk scores. *medRxiv* 2025.08. 29.25334745 (2025).

36. The International HapMap 3 Consortium. Integrating common and rare genetic variation in

diverse human populations. *Nature* **467**, 52–58 (2010).

37. Chang, C. C. *et al.* Second-generation PLINK: rising to the challenge of larger and richer

datasets. *Gigascience* **4**, (2015).

38. Eijsbouts, C. *et al.* Genome-wide analysis of 53,400 people with irritable bowel syndrome

highlights shared genetic pathways with mood and anxiety disorders. *Nat Genet* **53**, 1543–

1552 (2021).

39. Strom, N. I. *et al.* Genome-wide analyses identify 30 loci associated with obsessive–

compulsive disorder. *Nat Genet* **57**, 1389–1401 (2025).

40. Zeng, J. *et al.* Signatures of negative selection in the genetic architecture of human complex

traits. *Nat Genet* **50**, 746–753 (2018).

41. Gazal, S. *et al.* Functional architecture of low-frequency variants highlights strength of

negative selection across coding and non-coding annotations. *Nat Genet* **50**, 1600–1607

(2018).

42. Schoech, A. P. *et al.* Quantification of frequency-dependent genetic architectures in 25 UK

Biobank traits reveals action of negative selection. *Nat Commun* **10**, 790 (2019).

43. Simons, Y. B., Bullaughey, K., Hudson, R. R. & Sella, G. A population genetic interpretation

of GWAS findings for human quantitative traits. *PLoS Biol* **16**, e2002985 (2018).

44. Maier, R. *et al.* Joint Analysis of Psychiatric Disorders Increases Accuracy of Risk Prediction

for Schizophrenia, Bipolar Disorder, and Major Depressive Disorder. *The American Journal*

of Human Genetics **96**, 283–294 (2015).

45. Maier, R. M. *et al.* Improving genetic prediction by leveraging genetic correlations among

human diseases and traits. *Nat Commun* **9**, (2018).

46. Chung, W. *et al.* Efficient cross-trait penalized regression increases prediction accuracy in

large cohorts using secondary phenotypes. *Nat Commun* **10**, (2019).

47. Patel, A. P. *et al.* A multi-ancestry polygenic risk score improves risk prediction for coronary

artery disease. *Nat Med* **29**, 1793–1803 (2023).

48. Truong, B. *et al.* Integrative polygenic risk score improves the prediction accuracy of

complex traits and diseases. *Cell Genomics* **4**, 100523 (2024).

49. Finucane, H. K. *et al.* Partitioning heritability by functional annotation using genome-wide

association summary statistics. *Nat Genet* **47**, 1228–1235 (2015).

50. Finucane, H. K. *et al.* Heritability enrichment of specifically expressed genes identifies

disease-relevant tissues and cell types. *Nat Genet* **50**, 621–629 (2018).

51. Jagadeesh, K. A. *et al.* Identifying disease-critical cell types and cellular processes by

integrating single-cell RNA-sequencing and human genetics. *Nat Genet* **54**, 1479–1492

(2022).

52. Zhu, X. & Stephens, M. Large-scale genome-wide enrichment analyses identify new trait-

associated genes and pathways across 31 human phenotypes. *Nat Commun* **9**, (2018).

53. Kim, S. S. *et al.* Genes with High Network Connectivity Are Enriched for Disease

Heritability. *The American Journal of Human Genetics* **104**, 896–913 (2019).

54. Siewert-Rocks, K. M., Kim, S. S., Yao, D. W., Shi, H. & Price, A. L. Leveraging gene co-

regulation to identify gene sets enriched for disease heritability. *The American Journal of*

Human Genetics **109**, 393–404 (2022).

55. Grasby, K. L. *et al.* The genetic architecture of the human cerebral cortex. *Science* **367**,

eaay6690 (2020).

56. Smith, S. M. *et al.* An expanded set of genome-wide association studies of brain imaging

phenotypes in UK Biobank. *Nat Neurosci* **24**, 737–745 (2021).

57. Border, R. *et al.* Cross-trait assortative mating is widespread and inflates genetic correlation

estimates. *Science* **378**, 754–761 (2022).

58. Zhang, Y. *et al.* The contribution of gametic phase disequilibrium to the heritability of

complex traits. *Nat Genet* https://doi.org/10.1038/s41588-025-02192-4 (2025)

doi:10.1038/s41588-025-02192-4.

59. Benonisdottir, S. & Kong, A. Studying the genetics of participation using footprints left on

the ascertained genotypes. *Nat Genet* **55**, 1413–1420 (2023).

60. Schoeler, T. *et al.* Participation bias in the UK Biobank distorts genetic associations and

downstream analyses. *Nat Hum Behav* **7**, 1216–1227 (2023).

61. Zhou, W. *et al.* Global Biobank Meta-analysis Initiative: Powering genetic discovery across

human disease. *Cell Genomics* **2**, 100192 (2022).

62. The All of Us Research Program Genomics Investigators *et al.* Genomic data in the All of Us

Research Program. *Nature* **627**, 340–346 (2024).

63. Zhang, M. J. *et al.* Pervasive correlations between causal disease effects of proximal SNPs

vary with functional annotations and implicate stabilizing selection. Preprint at

https://doi.org/10.1101/2023.12.04.23299391 (2023).

64. The 1000 Genomes Project Consortium *et al.* A global reference for human genetic variation.

Nature **526**, 68–74 (2015).

65. Lee, S. H., Wray, N. R., Goddard, M. E. & Visscher, P. M. Estimating Missing Heritability

for Disease from Genome-wide Association Studies. *The American Journal of Human*

Genetics **88**, 294–305 (2011).

66. Jiang, X. *et al.* Age-dependent topic modeling of comorbidities in UK Biobank identifies

disease subtypes with differential genetic risk. *Nat Genet* **55**, 1854–1865 (2023).

67. Loh, P.-R. *et al.* Efficient Bayesian mixed-model analysis increases association power in

large cohorts. *Nat Genet* **47**, 284–290 (2015).

68. Loh, P.-R., Kichaev, G., Gazal, S., Schoech, A. P. & Price, A. L. Mixed-model association for

biobank-scale datasets. *Nat Genet* **50**, 906–908 (2018).

69. Kofink, D. *et al.* Statin Effects on Metabolic Profiles: Data From the PREVEND IT

(Prevention of Renal and Vascular End-stage Disease Intervention Trial). *Circ Cardiovasc*

Genet **10**, (2017).

70. Wu, J. *et al.* A Summary of the Effects of Antihypertensive Medications on Measured Blood

Pressure. *American Journal of Hypertension* **18**, 935–942 (2005).

71. Esposito, K., Chiodini, P., Colao, A., Lenzi, A. & Giugliano, D. Metabolic Syndrome and

Risk of Cancer. *Diabetes Care* **35**, 2402–2411 (2012).

Table 1. Overview of 15 UK Biobank diseases

Disease	Prevalence	h^2_{liab} (s.e.)	h^2 z-score	Category
Hypothyroidism	0.054	0.18 (0.024)	7.7	Endocrine
Type 2 diabetes	0.11	0.19 (0.014)	13	Endocrine
Obesity	0.20	0.14 (0.0087)	16	Endocrine
Depression	0.17	0.087 (0.0082)	11	Mental disorders
Tobacco use disorder	0.049	0.14 (0.017)	7.8	Mental disorders
Hypertension	0.37	0.21 (0.011)	19	Circulatory system
Coronary atherosclerosis	0.083	0.16 (0.015)	11	Circulatory system
Atrial fibrillation	0.051	0.12 (0.019)	6.2	Circulatory system
Varicose veins	0.069	0.12 (0.017)	6.9	Circulatory system
Respiratory diseases	0.30	0.061 (0.0061)	10	Respiratory
GERD	0.17	0.067 (0.0075)	9.0	Digestive
Inguinal hernia	0.074	0.11 (0.015)	7.1	Digestive
Diverticulosis	0.15	0.13 (0.010)	13	Digestive
Bunion	0.048	0.15 (0.018)	8.2	Musculoskeletal
Radiculitis	0.10	0.073 (0.010)	7.0	Symptoms

We report the names of 15 UK Biobank diseases, prevalence in UK Biobank, liability-scale heritability, heritability z-score, and the PheCode disease category. h^2_{liab} (s.e.) denotes the liability-scale heritability and its standard error; GERD denotes Gastroesophageal reflux disease. Full details refer to **Supplementary Table 1**.

Figure 1. Definition of pleiotropic heritability and pleiotropic phenotypic variance. (A) The total phenotypic variance of the target disease consists of genetic variance (G) and environmental variance (E). The genetic variance of the target disease is partitioned into a disease-specific component and a pleiotropic component. The disease-specific component is not shared with the auxiliary diseases, and the pleiotropic component consists of a linear combination of the genetic values (G_1, G_2, …, G_n) for auxiliary diseases 1 to n. Instances of G and E denote vectors of genetic and environmental values across individuals, and areas of rectangles denote variances. **(B)** The total phenotypic variance of the target disease is partitioned into a disease-specific component that is not shared with the auxiliary diseases, and a pleiotropic component that is shared with the auxiliary diseases. The pleiotropic phenotypic variance consists of a linear combination of total liabilities (L_1, L_2, …, L_n) for auxiliary diseases 1 to n. Instances of L denote vectors of total liabilities across individuals, and areas of rectangles denote variances.

1001

1002
Figure 2. **PHBC corrects upwards bias in simulations.** (A) Estimates of h^2_{pleio}/h^2 without
the bias correction step suffer upward bias. (B) Estimates of h^2_{pleio}/h^2 are approximately
unbiased after the Monte-Carlo bias correction. Each dot represents the mean of all estimates for
diseases with the same true value of h^2_{pleio}/h^2 across 100 simulations. Error bars denote
standard errors (but are generally smaller than dot size). Numerical results are reported in
Supplementary Table 4.
1009

Figure 3. **Estimates of genetic correlation and liability-scale phenotypic correlation**. (A) Estimates of genetic correlation across 15 UK Biobank diseases. (B) Estimates of liability-scale phenotypic correlation across 15 UK Biobank diseases. Asterisks denote pairs of diseases for which the genetic correlation is significantly larger than the liability-scale phenotypic correlation with Bonferroni-corrected $P < 4.76 \times 10^{-4}$ (= 0.05/105); no pairs have liability-scale phenotypic correlation significantly larger than the genetic correlation. Black boundaries demarcate correlations between diseases within the same disease category. Numerical results are reported in **Supplementary Table 15**.

Figure 4. h^2_{pleio}/h^2 **estimates for three representative diseases and the average across 15 UK Biobank diseases.** D+Q: h^2_{pleio}/h^2 estimates with respect to 15 UK Biobank auxiliary diseases and 17 UK Biobank quantitative auxiliary traits. D: h^2_{pleio}/h^2 estimates with respect to 15 UK Biobank auxiliary diseases. D\target: h^2_{pleio}/h^2 estimates with respect to 15 UK Biobank auxiliary diseases excluding those from the same disease category as the target disease. D\(target+best other): h^2_{pleio}/h^2 estimates with respect to 15 UK Biobank auxiliary diseases excluding those from the same disease category as the target disease and those from one other disease category whose removal had the greatest impact. Error bars denote jackknife standard errors. To assess statistical significance, we compare average estimates from D+Q, D\target and D\(target+best other) to estimates from D using inverse-variance weighting across diseases/traits. *: $P < 0.05$; **: $P < 0.001$. T2D: type 2 diabetes; MDD: depression; HTN: hypertension. Numerical results are reported in **Supplementary Tables 17 and 18**.

Figure 5. h^2_{pleio}/h^2 **is broadly shared across PheCode disease categories.** (A-C) Comparison between h^2_{pleio}/h^2 using a single auxiliary disease category (light bars) and the reduction in h^2_{pleio}/h^2 when removing the auxiliary disease category (dark bars), for three representative UK Biobank diseases (depression, type 2 diabetes, hypertension) and the average across 15 UK Biobank diseases. Error bars denote jackknife standard errors. Numerical results are reported in **Supplementary Table 19**.

1044

Figure 6. h^2_{pleio}/h^2 **estimates with respect to different sets of auxiliary diseases/traits.** (A)

h^2_{pleio}/h^2 estimates for three representative UK Biobank diseases and the average across 15 UK

Biobank diseases with respect to four sets of auxiliary diseases/traits. (B) h^2_{pleio}/h^2 estimates

for three representative non-UK Biobank diseases and the average across 30 non-UK Biobank

diseases with respect to four sets of auxiliary diseases/traits. Error bars denote jackknife standard

errors. To assess statistical significance, we compare average estimates from 30 non-UK

Biobank auxiliary diseases, all 45 auxiliary diseases, and all 62 auxiliary diseases and

quantitative traits to estimates from 15 UK Biobank auxiliary diseases using inverse-variance

weighting across diseases/traits: * $P < 0.05$; ** $P < 0.001$. Numerical results are reported in

Supplementary Tables 18, 22 and **23**.

1055

1056
1057 **Figure 7. Comparison of h^2_{pleio}/h^2 vs. V^2_{pleio}/V^2 for 15 diseases in UK Biobank.** Colored
1058 dots denote diseases for which h^2_{pleio}/h^2 estimates are significantly different from V^2_{pleio}/V^2
1059 estimates ($P < 0.05/15$). Numerical results are reported in **Supplementary Table 26**. MDD:
1060 depression; T2D: type 2 diabetes; HTN: hypertension; GERD: gastroesophageal reflux disease.
1061
1062